Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to

  • 15 views
  • 02 Jul, 2022
  • 19 locations
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the investigator

metastasis
androgen suppression
abiraterone
enzalutamide
orchiectomy
  • 14 views
  • 04 Mar, 2022
  • 2 locations
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28

  • 0 views
  • 19 Jun, 2022
  • 4 locations
Study of Copanlisib and Ketogenic Diet

This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies

cancer
PIK3CA
ejection fraction
PTEN
follicular lymphoma
  • 0 views
  • 15 Dec, 2021
  • 1 location
Lung Cancer With Copanlisib and Durvalumab

with a goal of cure. The overall hypothesis of this study is that the addition of Copanlisib to Durvalumab will be well-tolerated at a biweekly schedule. It will test whether the addition of Copanlisib

lung carcinoma
measurable disease
durvalumab
stage iii non-small cell lung cancer
  • 0 views
  • 29 May, 2021
  • 1 location
Copanlisib Plus Venetoclax in R/R DLBCL

This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names

  • 0 views
  • 30 May, 2022
  • 1 location
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

. The PI3K inhibitor Copanlisib has shown high clinical activity in indolent B - cell lymphomas among them MZL. Based on these observations it is the aim of this study to test the toxicity and efficacy

remission
interferon
splenic marginal zone lymphoma
rituximab
tositumomab
  • 10 views
  • 21 Apr, 2022
  • 10 locations
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

also being done to find out the highest doses of copanlisib and vemurafenib that, when given in combination, do not cause serious side effects, and whether the study treatment will make radioiodine

metastasis
absolute neutrophil count
avid
pet/ct scan
lipase
  • 0 views
  • 17 Mar, 2022
  • 7 locations
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

This research study is examining the effect of adding a fixed duration of copanlisib to ibrutinib or acalabrutinib in select participants who have been on ibrutinib or acalabrutinib for at least

gilbert's syndrome
chronic lymphocytic leukemia
acalabrutinib
ibrutinib
lymphadenopathy
  • 0 views
  • 02 Jun, 2022
  • 1 location
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

This phase I trial studies the best dose and how well copanlisib when given together with nivolumab works in treating patients with Richter's transformation or transformed indolent non-Hodgkin

hodgkin's disease
diffuse large b-cell lymphoma
indolent lymphoma
rituximab
cyclophosphamide
  • 17 views
  • 09 Apr, 2022
  • 2 locations